LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT DATED AS OF SEPTEMBER 7, 2010 BY AND AMONG ONYX PHARMACEUTICALS, INC. AND ONYX THERAPEUTICS, INC. AND ONO PHARMACEUTICAL CO., LTD.License, Development and Commercialization Agreement • November 3rd, 2010 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
This License, Development and Commercialization Agreement (this “Agreement”), dated as of September 7, 2010 (the “Effective Date”), is made by and among Onyx Pharmaceuticals, Inc., a Delaware corporation, and Onyx Therapeutics, Inc., a Delaware corporation (together referred to as, “Onyx”), and Ono Pharmaceutical Co., Ltd., a Japanese stock corporation (“Ono”). Onyx and Ono are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
Re: Separation and Consulting AgreementSeparation and Consulting Agreement • November 3rd, 2010 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Delaware
As discussed, this letter sets forth the terms of the separation and consulting agreement (the “Agreement”) between you and Onyx Pharmaceuticals, Inc. (“Onyx” or the “Company”).
